Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Aust first for myeloma drug

Posted 19 October 2020

Australian multiple myeloma patients could be the first in the world to have access to the drug Aplidin through an exclusive license agreement held by Victorian-based pharmaceutical company Specialised Therapeutics Australia (STA).

Under an agreement with PharmaMar, headquartered in Madrid, STA is bringing the drug down under.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
UPDATES: UNICEF stockpiling one billion syringes
Approvals Action
Shakeup for insulin
New biosim plus hypertension and herpes generics
Top of the Hill
Avoiding the Emperor's mistake
Not everyone is convinced about industry's budget win